PCRX$23.46
Chart
Performance
Key Stats
AI PCRX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyPacira BioSciences exhibits moderate fundamental strength with strong revenue growth and a healthy balance sheet. Thematic tailwinds in pain management are positive, but current technical indicators suggest a cautious approach due to a bearish short-term trend.
Thematic
Pacira BioSciences is well-positioned within the expanding non-opioid pain management and regenerative health markets, benefiting from increasing demand for alternatives to opioids and advancements in gene therapy.
Fundamental
Pacira BioSciences demonstrates solid revenue growth and improving profitability, supported by a healthy balance sheet. However, the recent shift to net losses and a high debt-to-equity ratio warrant attention.
Technical
The stock is experiencing downward price pressure, trading below key moving averages, and showing bearish momentum indicators. Support levels are being tested, suggesting potential for further declines in the short term.
| Factor | Score |
|---|---|
| Non-Opioid Pain Management | 90 |
| Regenerative Health & Gene Therapy | 85 |
| Healthcare Innovation & R&D | 80 |
| Aging Population & Chronic Pain | 80 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 35 |
| Growth | 60 |
| Balance Sheet Health | 50 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 60 |
| Short-Term Trend | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
Pacira BioSciences, Inc. (PCRX) has consistently beaten EPS estimates in recent quarters. For example, in Q1 2025, actual EPS of $0.62 exceeded the estimate of $0.60, and in Q4 2024, actual EPS of $0.79 beat the estimate of $0.70.
Revenue Growth Momentum
Annual revenue has shown growth from $541.5 million in 2021 to $700.9 million in 2024. Quarterly revenue has also seen positive trends, with Q1 2025 revenue at $168.9 million and Q4 2024 revenue at $187.2 million.
Bearish Points (7)
Recent Net Loss
The company reported a net loss of -$99.56 million in 2024 and a negative TTM net income of -$122.61 million, suggesting ongoing profitability challenges.
Negative Earnings Per Share (EPS)
The EPS TTM is negative at -2.24, which can make traditional valuation metrics like P/E ratio less meaningful and indicates current unprofitability on a per-share basis.
Calendar
August 2025
6
Next Earnings Date
H: $0.81
A: $0.71
L: $0.64
H: 185.50M
A: 183.12M
L: 180.22M
Profile
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Seasonals
Price Target
30.40 USD
The 39 analysts offering 1 year price forecasts for PCRX have a max estimate of 44.00 and a min estimate of 24.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in post-surgical non-opioid pain management with ZYNRELEF, a long-acting local anesthetic that competes with Pacira's EXPAREL.
Weight: 90
Specializes in pain management, including abuse-deterrent opioids and non-opioid alternatives, actively competing in the broader pain market and for market share in acute pain.
Weight: 88
Focuses on acute care, with Anjeso (meloxicam) for acute pain, directly competing in the non-opioid acute pain space relevant to surgical recovery.
Weight: 85
Developer of DSUVIA, a sufentanil sublingual tablet for acute pain, which, while an opioid, aims to reduce IV opioid use in medically supervised settings, competing for acute pain market share.